Abstract
AbstractMetallo-β-lactamases (MBL) are a threat to public health, since they dramatically limit the use of β-lactams. We report the isolation of a multidrug-resistant Hafnia paralvei strain from urine and a rectal swab of a female patient after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome. Antimicrobial susceptibility testing yielded resistance to trimethoprim/sulfamethoxazole, colistin, fosfomycin and all β-lactams, except cefiderocol. Whole genome sequencing revealed the presence of plasmid-encoded NDM-1 and VIM-1 carbapenemases. This finding highlights the importance of epidemiological surveillance and new therapeutic options for MBL.
Funder
Universitätsklinikum Jena
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference10 articles.
1. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet [Internet]. 2022 Feb 12 [cited 2022 Apr 12];399(10325):629–55. Available from: 10.1016/
2. Huys G, Cnockaert M, Abbott SL, Janda JM, Vandamme P. Hafnia paralvei sp. nov., formerly known as Hafnia alvei hybridization group 2. Int J Syst Evol Microbiol [Internet]. 2010 Aug 1 [cited 2022 Apr 11];60(8):1725–8. Available from: https://www.microbiologyresearch.org/content/journal/ijsem/https://doi.org/10.1099/ijs.0.018606-0
3. Skurnik D, Nucci A, Ruimy R, Lasocki S, Muller-Serieys C, Montravers P, et al. Emergence of carbapenem-resistant hafnia: the fall of the last soldier. Clin Infect Dis [Internet]. 2010 May 15 [cited 2022 Apr 11];50(10):1429–31. Available from: https://academic.oup.com/cid/article/50/10/1429/378396
4. Mojica MF, Bonomo RA, Fast W. B1-Metallo-β-lactamases: where do we stand? Curr Drug Targets [Internet]. 2016 [cited 2019 Jul 29];17(9):1029–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26424398
5. García-Betancur JC, Appel TM, Esparza G, Gales AC, Levy-Hara G, Cornistein W, et al. Update on the epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther. 2021;19(2):197–213.